Important note: Information in this article was accurate in April 2007. The state of the art may have changed since the publication date.
 |
AIDSWEEKLY Plus; Monday, April 2, 2007
Staff Medical Writers
BIT225 represents a novel, first in class approach to the treatment of HIV. BIT225 specifically targets HIV in reservoir cells and represents an opportunity to attack HIV at its source in the body. Current HIV therapies have little or no effect on HIV in the underlying reservoir of infected cells where the virus hides from the immune system.
In addition, BIT225 has demonstrated good antiviral activity in surrogate models of Hepatitis C virus ('HCV') infection. This human safety trial of BIT225 will support trials of the drug in both HIV and HCV infected patients, to commence on conclusion of the Phase I study.
"The initiation of clinical testing of Biotron's HIV inhibitor is a major milestone for the Company" said Michelle Miller, Ph.D., Biotron's Managing Director. "This progression into human studies marks the transition of Biotron from an R&D focused company to an antiviral drug development company with an exciting portfolio of clinical development programs". The trial is due for completion in the second quarter of 2007.
Keywords: HIV/AIDS, AIDS, Acquired Immunodeficiency Syndrome, Clinical Trial Research, Drug Development, HIV, Human Immunodeficiency Virus, Pharmaceuticals, Therapy, Treatment, Virology, Biotron.
This article was prepared by AIDS Weekly editors from staff and other reports.
2007-04-02
AW070403
Copyright © 2007 - Charles Henderson, Publisher. All rights Reserved. Permission to reproduce granted to AEGIS by Charles W. Henderson. Authorization to reproduce for personal use granted granted by C. W. Henderson, Publisher, provided that the fee of US$4.50 per copy, per page is paid directly to the Copyright Clearance Center, 27 Congress Street, Salem, Massachusetts 01970, USA. Published by Charles Henderson, Publisher. Editorial & Publishing Office: P.O. Box 5528, Atlanta, GA 30307-0528 / Telephone: (800) 633-4931; Subscription Office: P.O. Box 830409, Birmingham, AL 35283-0409 / FAX: (205) 995-1588 http://www.newsrx.net
AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, Bridgestone/Firestone Charitable Trust, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2007. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright © 1980,2007. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.